

Anti-Hemophilic FACTOR VIII PLUS VWF Complex (Human) 1IU J7186, Humate J7187, Wilate J7183 Prior Authorization Request Medicare Part B Form

Instructions: * Indicates required information – Form may be returned if required information is not provided. Please fax this request to the appropriate fax number listed at the bottom of the page.

□ Standard Request– (72 Hours)				Urgent Request (standard time frame could place the member's life, health or ability in serious jeopardy)					
Date Requested									
	Requestor Clinic name: _			Phone / Fax					
MEMBER INFORMATION									
				#:*DOB:					
PRESCRIBER INFORMATION									
*Name: □M				D □FNP □DO □NP □PA *Phone:					
*Address:				*Fax:					
DISPENSING PROVIDER / ADMINISTRATION INFORMATION									
			Phone:						
*Address:Fax:Fax:									
	700				_	End Date if			
НС	PC Code	Name of Drug	Dos	e (Wt:	kg Ht:)	Frequency	known	
□ Self-administered □ Provider-administered □ Home Infusion									
□ Chart notes attached. Other important information:									
Diagnosis: ICD10: Description:									
☐ Provider attests the diagnosis provided is an FDA-Approved indication for this drug									
CLINICAL INFORMATION									
 □ New Start or Initial Request: (Clinical documentation required for all requests) □ Provider has reviewed the attached "Criteria for Approval" and attests the member meets ALL required PA criteria. If not, please provide clinical rationale for formulary exception: 									
 □ Continuation Requests: (Clinical documentation required for all requests) □ Provider has reviewed the attached "Criteria for Continuation" and attests the member meets ALL required PA Continuation criteria. □ Patient had an adequate response or significant improvement while on this medication. If not, please provide clinical rationale for continuing this medication: 									
ACKNOWLEDGEMENT									
Request By (Signature Required):									



Prior Authorization Group - Coagulation Factors PA

Drug Name(s):

FACTOR VIII PLUS VWF Complex (Human) 1IU Humate
Wilate

Criteria for approval of Non-Formulary/Preferred Drug:

- 1. Prescribed for an approved FDA diagnosis (as listed below):
- 2. Member does not have any clinically relevant contraindications, or CMS/Plan exclusions, to the requested drug.
- If the member meets all these criteria, they may be approved by the Plan for the requested drug.
- Quantity limits and Tiering will be determined by the Plan.

Exclusion Criteria:

N/A

Prescriber Restrictions:

N/A

Coverage Duration:

Approval will be for 12 months

FDA Indications:

Factor VIII + VWF, Humate, Wilate

- 1. Patient has a diagnosis of hemophilia A
 - a. Treatment of on-demand bleeding episodes/hemorrhage OR
 - b. Routine prophylaxis of hemorrhage
- 2. Patient has a diagnosis of Von Willebrand disorder
 - a. Treatment of on-demand bleeding episodes/hemorrhage OR
 - b. Perioperative management of hemorrhage

Off-Label Uses:

N/a

Age Restrictions:

N/A

Other Clinical Consideration:

N/A

Resources:

https://www.micromedexsolutions.com/micromedex2/librarian/CS/53A877/ND_PR/evidencexpert/ND_P/evidencexpert/DUPLICATIONSHIELDSYNC/7C20F6/ND_PG/evidencexpert/ND_B/evidencexpert/ND_AppProduct/evidencexpert/ND_T/evidencexpert/PFActionId/evidencexpert.DoIntegratedSearch?SearchTerm=Antihemophilic%20Factor%20VIII%2FVon%20Willebrand%20Factor%20(Human)&UserSearchTerm=Antihemophilic%20Factor%20VIII%2FVon%20Willebrand%20Factor%20(Human)&SearchFilter=filterNone&navitem=searchGlobal#